# Pharmacogenomics in Pulmonary Arterial Hypertension

> **NCT00593905** · — · WITHDRAWN · sponsor: **West Penn Allegheny Health System**

## Conditions studied

- Pulmonary Arterial Hypertension
- Pulmonary Hypertension
- PAH WHO Group I

## Interventions

- **DRUG:** Sitaxsentan
- **DRUG:** Bosentan, Ambrisentan

## Key facts

- **NCT ID:** NCT00593905
- **Lead sponsor:** West Penn Allegheny Health System
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2005-07
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** study not started not an ACT
- **Last updated:** 2021-12-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00593905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00593905, "Pharmacogenomics in Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00593905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*